TABLE 2.
Clinical trials of the CRISPR/Cas9 system.
| Target | Therapy | Clinicaltrials.gov number | Reference |
|---|---|---|---|
| CCR5 | HIV | NCT00842634 | Tebas et al. (2014) |
| NCT03164135 | Xu et al. (2019) | ||
| BCL11A | Sickle-cell anemia (SCD) and β-thalassemia | NCT03745287 | Basak and Sankaran, (2016) |
| NCT03655678 | Frangoul et al. (2021) | ||
| PDCD1 (PD-1) | Non-small-cell lung cancer (NSCLC) | NCT02793856 | Lu et al. (2020) |
| Advanced refractory myeloma and metastatic sarcoma | NCT03399448 | Stadtmauer et al. (2020) | |
| Relapsed/refractory acute lymphoblastic leukemia (r/r ALL) | NCT04227015 | Hu et al. (2021) | |
| Mesothelin-positive solid tumors | NCT03545815 | Wang et al. (2021) | |
| Metastatic colorectal cancer | NCT03174405 | Stein et al. (2021) | |
| Prostate cancer | NCT02867345 | Yi and Li, (2016) | |
| Bladder cancer | NCT02863913 | ||
| Metastatic renal cell carcinoma | NCT02867332 | ||
| E6 and E7 | HPV | NCT03057912 | Khairkhah et al. (2022) |
| RPE65 | Leber’s congenital amaurosis type 10 (LCA10) | NCT03872479 | Maeder et al. (2019) |
| TTR | Transthyretin amyloidosis (ATTR amyloidosis) | NCT04601051 | Gillmore et al. (2021) |